Wealthspire Advisors LLC Cuts Stock Holdings in Edwards Lifesciences Corporation $EW

Wealthspire Advisors LLC cut its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 17.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,556 shares of the medical research company’s stock after selling 1,823 shares during the period. Wealthspire Advisors LLC’s holdings in Edwards Lifesciences were worth $669,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Econ Financial Services Corp purchased a new stake in shares of Edwards Lifesciences during the second quarter worth $889,000. Pacific Capital Partners Ltd purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $1,760,000. Arkadios Wealth Advisors acquired a new position in Edwards Lifesciences during the second quarter worth about $300,000. Randolph Co Inc purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at about $301,000. Finally, Mirova US LLC raised its holdings in Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.1%

Shares of EW stock opened at $85.02 on Friday. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.21. The firm has a market cap of $49.34 billion, a PE ratio of 12.23, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The company has a 50-day moving average of $78.80 and a two-hundred day moving average of $78.04. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business posted $0.67 EPS. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on EW. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 29th. Canaccord Genuity Group restated a “hold” rating and issued a $84.00 target price (up from $81.00) on shares of Edwards Lifesciences in a report on Monday, November 3rd. Piper Sandler reissued an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Truist Financial raised their price objective on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a research report on Monday, November 3rd. Finally, Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.